BioCentury | Mar 27, 2021
Regulation
March 26 Quick Takes: ADCs from Astellas-Seagen, Gilead under EMA review; plus Pfizer-Lilly, BrainStorm and Ilya
EMA to review Padcev for urothelial cancerAstellas Pharma Inc. (Tokyo:4503) and Seagen Inc. (NASDAQ:SGEN) said EMA accepted an MAA for Padcev enfortumab vedotin, an antibody-drug conjugate (ADC) targeting PRR4, to treat locally advanced or metastatic urothelial...